NasdaqGS:INCYBiotechs
Incyte (INCY) Could Be 5% Overvalued Following Opzelura Approval And Higher Guidance
Incyte (INCY) has been in focus after the European Commission approved Opzelura cream for moderate atopic dermatitis in adults, and the company reported strong second quarter earnings along with higher full year sales guidance.
See our latest analysis for Incyte.
Incyte’s recent approvals and higher guidance have arrived alongside a mixed but generally positive share price trend, with the stock posting a 20.78% 90 day share price return and a 55.16% 1 year total shareholder return, indicating...